Elena Ridloff is the Chief Financial Officer of Sionna Therapeutics, a life sciences company founded in 2019 to develop differentiated treatments for cystic fibrosis. Previously, Ms. Ridloff was Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals, where she was responsible for leading the corporate finance, accounting, investor relations and corporate affairs functions. Prior to Acadia, Ms. Ridloff was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee. Prior to that, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm serving the life sciences industry. Earlier in her career, she spent more than a decade as an institutional investor in the biopharmaceutical industry, including as a Managing Director at Maverick Capital, a hedge fund where she was responsible for investments in the biotechnology and life science sectors. Ms. Ridloff received her B.A. in History and Sociology of Science from the University of Pennsylvania and is a CFA© charterholder.
Ms. Ridloff also currently serves on the Board of directors for Kymera Therapeutics.